Article
In silico identification of EGFR-T790M inhibitors with novel scaffolds: start with extraction of common features.
Drug design, development and therapy - 1 Jan 2013
Xiang Mingli, Lei Kai, Fan Wenjie, Lin Yuchun, He Gu, Yang Mingli, Chen Lijuan, Mo Yirong
Abstract excerpt
BACKGROUND: Epidermal growth factor receptor (EGFR) is an attractive therapeutic target for a number of human tumors including non-small cell lung cancer (NSCLC). Most patients with NSCLC and somatic mutations have shown a dramatic initial clinical response to reversible EGFR inhibitors. The clinical efficacy of reversible inhibitors is, however, ultimately limited due to the emergence of drug resistance, which...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.